New drug targets rare gene mutations in advanced cancers
NCT ID NCT04233567
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested the drug infigratinib in 17 adults with advanced or metastatic solid tumors that have specific FGFR gene mutations. The drug works by blocking overactive FGFR proteins that help cancer grow. The study measured how many patients' tumors shrank or stabilized, and how long that lasted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Infigratinib (a drug that blocks FGFR proteins to slow tumor growth)
- What this could lead to
- If successful, this could point toward a targeted treatment option for people with certain FGFR-mutated cancers that are hard to treat.
- What could go wrong
- This is a small, early-phase trial (17 people) with no control group, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors in many patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?